Table 4 Effects of DHS and DMS on muscarine-induced reductions in luminal airway area in PCLS from M3 R-KO and their corresponding wild-type mice. The number of experiments (lungs/slices), mean airway diameter in μm, and the muscarine-induced constriction in luminal airway area (expressed in %) determined after 1 min (1) and 15 min (2) after stimulation with muscarine and 1 min (3) and 15 min (4) after stimulation with muscarine in combination with DHS or DMS (both 10-6 M or 10-8 M) are shown. In all experiments, the muscarine concentration was 10-6 M. The initial phase (1 vs 3) and the sustained phase (2 vs 4) of constriction were reduced in presence of DHS or DMS. Data are given as means ± S.E.M.
M3R-wt Lungs /slices | Diameter [μm] | Area [%] 1 | Area [%] 2 | Area [%] 3 | Area [%] 4 | p (1 vs. 3) | p (2 vs. 4) |
|---|---|---|---|---|---|---|---|
6/6 | 221 ± 10 | Mus | Mus/DHS 10-6 M | n.s. | p ≤ 0.05 | ||
53 ± 7 | 47 ± 8 | 75 ± 7 | 69 ± 11 | ||||
8/9 | 204 ± 10 | Mus | Mus/DHS 10-8 M | p ≤ 0.05 | p ≤ 0.01 | ||
40 ± 6 | 30 ± 6 | 64 ± 9 | 55 ± 6 | ||||
6/7 | 203 ± 6 | Mus | Mus/DMS 10-6 M | p ≤ 0.05 | p ≤ 0.05 | ||
41 ± 10 | 37 ± 8 | 64 ± 10 | 56 ± 8 | ||||
5/6 | 197 ± 8 | Mus | Mus/DMS 10-8 M | p ≤ 0.05 | p ≤ 0.05 | ||
42 ± 5 | 41 ± 10 | 71 ± 7 | 69 ± 9 | ||||
M3R-KO | |||||||
4/4 | 205 ± 18 | Mus | Mus/DHS 10-6 M | n.s. | n.s. | ||
69 ± 2 | 51 ± 4 | 77 ± 8 | 62 ± 12 | ||||
8/9 | 188 ± 9 | Mus | Mus/DHS 10-8 M | p ≤ 0.05 | p ≤ 0.05 | ||
75 ± 6 | 67 ± 6 | 96 ± 2 | 88 ± 4 | ||||
7/7 | 202 ± 12 | Mus | Mus/DMS 10-6 M | p ≤ 0.05 | p ≤ 0.05 | ||
75 ± 4 | 67 ± 6 | 97 ± 1 | 82 ± 4 | ||||
9/9 | 196 ± 7 | Mus | Mus/DMS 10-8 M | p ≤ 0.01 | p ≤ 0.05 | ||
65 ± 5 | 56 ± 6 | 93 ± 2 | 81 ± 3 | ||||